Since 1994, several different inactivated rabies vaccines have been used to immunize domestic animals such as dogs, cats, and cattle in South Korea. The Korean Veterinary Authority has conducted safety and efficacy testes of inactivated vaccines using laboratory animals. In this study, we applied a molecular method to investigate the genetic characterization of the rabies virus (RABV) genes in six commercial inactivated rabies vaccines, and determined the efficiency of two extraction reagents (i.e., sodium citrate or isopropyl myristate) to separate the vaccine antigens from the antigen/ adjuvant complexes. Six partial nucleocapsid (N: 181 bp) and five partial glycoprotein (G: 306 bp) genes were successfully amplified with specific primer sets, which demonstrated that sodium citrate is more efficient than isopropyl myristate in extracting viral RNA from inactivated gel vaccines. In addition, we identified the viral strain of the vaccine by analyzing the nucleotide sequences of the N and the G genes. The nucleotide similarity of the partial N and G genes ranged from 97.1 to 99.4% and from 91.8 to 100% among rabies vaccine strains, respectively, indicating that each manufacturer used different rabies virus strains to produce their vaccines. The molecular method used in this study could also be used to identify viral strains in other inactivated vaccines.
INTRODUCTION

Rabies is one of the most important infectious diseases
as it is almost invariably fatal in animals and humans (1) .
According to the World Health Organization (WHO), rabies infections result in approximately 55,000 human deaths worldwide every year (2) . In South Korea, since the first case of rabies was reported in 1907, a number of additional rabies cases have been reported (3~5). Two types of inactivated rabies vaccines were manufactured in 1945 and 1959. The first was made from infected rabbit brain or spinal cord tissue after then the rabies virus (RABV) was inactivated with phenol or merthiolate. The second type was manufactured using calf brain and spinal cord tissue that was infected with wild RABV. Unfortunately, these inactivated vaccines provided short-acting immunity as they contained the small amount of RABV, and had many adverse effects due to tissue debris present in vaccines (6, 7) . The first live rabies vaccine, which was used during the 1960~1980s, was made from a chicken embryo infected with the Flury-LEP viral strain. The live virus also had several drawbacks including a complicated production process, high production costs and severe unintended side effects. The second live vaccine, which used the ERA (Evelyn-Rokitnicki-Abelseth) strain, was introduced from Canada in 1974; it was cloned by several limit dilutions and by propagating the ERA strain 47 in primary porcine kidney cells in 1980 (8) . Until recently, this is the vaccine that was used to immunize dogs. Although live attenuated vaccines are considered safe in several countries, including South Korea, the use of inactivated cell culture vaccines is increasing around the world. In addition, the WHO does not recommend live vaccines for parenteral use in animals (9) . As a result, in 1994, the Korean Veterinary Authority permitted the use of seven inactivated rabies vaccines for immunizing pets and other species of animals such as dogs, cats, cattle, goats, and fox. Laboratory animals have been used to monitor the efficacy of the vaccines. However, it is difficult to measure the quantity of vaccine antigen without conducting immunogenicity studies with animals, because the vaccine strain is killed by inactivating agents such as formalin and binary ethylenimine (BEI) during the manufacturing process. In addition, identification of antigen in the inactivated rabies vaccine is difficult as the antigen is mixed with adjuvant and has no special features like hemagglutination activity. To overcome these difficulties in identification of the RABV antigen, we used a molecular method to amplify the target gene of the viral RNA extracted from six commercially available inactivated rabies vaccines. This study also investigated the extraction condition of the antigen from commercially available inactivated gel-type rabies vaccines and compared the genetic characterization of rabies vaccine strains using generalized reverse transcription polymerase chain reaction (RT-PCR) and nucleotide sequence analysis.
MATERIALS AND METHODS
Vaccines and pretreatments
Inactivated rabies vaccines from six different manufacturers were used. Two methods were used to recover RABV antigen from the gel vaccines. First, 200 μl of the inactivated vaccine were mixed thoroughly with 800 μl isopropyl myristate (Sigma, Steinbeim, Germany) for 5 min.
The mixture was centrifuged at 3,000 × g for 10 min, and the water phase was collected and used for the extraction of RNA. Second, 1 ml of inactivated vaccine was mixed with 0.1 g of sodium citrate (Sigma) on a rotator at 37℃ for 12 hrs. The mixtures were frozen and thawed three times and centrifuged at 7,000 × g for 5 min, and the supernatant was then collected and used for the extraction of RNA.
Extraction of viral RNA and RT-PCR
Viral RNA was extracted from the six inactivated vaccines using an RNA extraction kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The extracted RNA was diluted in 50 μl of RNase-and DNase-free water.
RT-PCR was performed using specific primer sets (RVNF, RVNR, RVGF, and RVGR) that amplify the nucleocapsid (N) and glycoprotein (G) gene of RABV ( Table 1 ). The RT-PCR was performed in a reaction mixture containing 2 μl of denatured RNA, 1 μl of each primer (50 pmol), 10 μl of 5× buffer (12.5 mM MgCl 2 ), 2 μl of dNTP mix, 2 μl of enzyme mix (reverse transcriptase and Taq polymerase), and 32 μl of distilled water (Qiagen, Hilden, Germany). The cycling profile consisted of cDNA synthesis at 42℃ for 30 min, followed by 35 cycles of 95℃ for 45 sec, 55℃ for 45 sec, and 72℃ for 1 min, with a final extension at 72℃ for 5 min. The PCR products were visualized using electrophoresis on 1.8% agarose gels containing ethidium bromide.
Cloning and sequencing
All PCR products that were purified using the gel extrac- The fluorescent-labeled fragments were purified from the unincorporated terminators using an ethanol precipitation protocol. The samples were resuspended in distilled water and then subjected to electrophoresis in an ABI 3730xl
sequencer (Applied Biosystems, USA). Both DNA strands were sequenced to verify the sequences.
Phylogenetic analysis
Nucleotide sequence similarities were calculated using the DNASIS (Hitachi Software, Japan) software. Individual sequences were initially aligned using BioEdit and Clustal X 1.81. Phylogenetic reconstructions were generated using the neighbor-joining (NJ) method by the computer program PHYLIP 3.572c. Phylogenetic trees were reconstructed on aligned nucleotide sequences using ClustalW (version 2.0.12, UK). The robustness of the phylogenetic analysis was determined by bootstrap analysis with 1,000 replications. 
RESULTS
RT-PCR according to pretreatments
Before extracting the viral RNA from the inactivated vaccines, two reagents (sodium citrate or isopropyl myristate)
were used to separate RABV antigens from the antigen/ adjuvant complex in the vaccine. Four N genes specific positive reactions were detected when sodium citrate was used to recover RABV antigens, while two positive reactions were amplified when isopropyl myristate was used ( with sodium citrate, while one G gene specific reaction was amplified with isopropyl myristate ( Fig. 2A and B) . Overall, a 306-bp fragment was found in five of six inactivated rabies vaccines that were amplified with the G gene primer set. analyze the relationship of rabies vaccine strains. The phylogenetic tree based on the nucleotide sequence analysis of the N gene revealed that rabies vaccine strains were divided into three clusters (Fig. 3) . The nucleotide similarity of the partial N gene ranged from 97.1 to 99.4% among the six rabies vaccine strains and 91.1 to 94.5% between the Korean RABV field isolates and the inactivated vaccine strains.
The phylogenetic tree based on the nucleotide sequence of the partial G gene demonstrated that rabies vaccine strains also divided into three clusters (Fig. 4) . The deduced amino acid analysis of the partial G gene showed that the PV11-related group had a total of 13 amino acid changes from the CVS related group and that the amino acid similarity of the partial G gene among five of the RABV vaccine strains ranged from 82.9 to 100%. 
